[go: up one dir, main page]

DK1692181T3 - Leptinantagonist og fremgangsmåde til kvantitativ måling af leptin - Google Patents

Leptinantagonist og fremgangsmåde til kvantitativ måling af leptin

Info

Publication number
DK1692181T3
DK1692181T3 DK04797956.2T DK04797956T DK1692181T3 DK 1692181 T3 DK1692181 T3 DK 1692181T3 DK 04797956 T DK04797956 T DK 04797956T DK 1692181 T3 DK1692181 T3 DK 1692181T3
Authority
DK
Denmark
Prior art keywords
leptin
quantitative measurement
antagonist
binding
antibody
Prior art date
Application number
DK04797956.2T
Other languages
English (en)
Inventor
Christian J Strasburger
Martin Bidlingmaier
Zida Wu
Richard J M Ross
Giuseppe Matarese
Original Assignee
Klinikum Der Uni Muenchen
Univ Sheffield
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klinikum Der Uni Muenchen, Univ Sheffield filed Critical Klinikum Der Uni Muenchen
Application granted granted Critical
Publication of DK1692181T3 publication Critical patent/DK1692181T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74Inducing cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
DK04797956.2T 2003-11-17 2004-11-17 Leptinantagonist og fremgangsmåde til kvantitativ måling af leptin DK1692181T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10353593A DE10353593A1 (de) 2003-11-17 2003-11-17 Leptinantagonist und Verfahren zur quantitativen Messung von Leptin
PCT/EP2004/013043 WO2005049655A1 (en) 2003-11-17 2004-11-17 Leptin antagonist and method for quantitative measurement of leptin

Publications (1)

Publication Number Publication Date
DK1692181T3 true DK1692181T3 (da) 2012-04-30

Family

ID=34609036

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04797956.2T DK1692181T3 (da) 2003-11-17 2004-11-17 Leptinantagonist og fremgangsmåde til kvantitativ måling af leptin

Country Status (10)

Country Link
US (1) US7807154B2 (da)
EP (1) EP1692181B1 (da)
JP (1) JP2007536212A (da)
CN (1) CN1984930A (da)
AT (1) ATE540979T1 (da)
AU (1) AU2004291323A1 (da)
DE (1) DE10353593A1 (da)
DK (1) DK1692181T3 (da)
ES (1) ES2380341T3 (da)
WO (1) WO2005049655A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7320868B2 (en) 2004-03-19 2008-01-22 Arieh Gertler Leptin binding domain compositions and methods thereto
US8969291B2 (en) * 2004-10-08 2015-03-03 Enzo Therapeutics, Inc. Methods for decreasing leptin levels or activity for treating inflammation
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US8716220B2 (en) * 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
EP2326339A4 (en) * 2008-05-21 2012-06-20 Neurotez Inc METHOD FOR TREATING PROGRESSIVE COGNITIVE DISORDER IN CONNECTION WITH NEUROFIBRILLARY TANGLES
WO2009149149A1 (en) * 2008-06-04 2009-12-10 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations
EP2663579B1 (en) 2011-01-14 2017-04-26 The Regents of the University of California Therapeutic antibodies against ror-1 protein and methods for use of same
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
GB201113354D0 (en) 2011-08-03 2011-09-21 Univ Sheffield Leptin receptor structure
CN104459105B (zh) * 2014-12-05 2016-03-09 重庆中元生物技术有限公司 一种检测lp的胶乳增强免疫比浊试剂盒及其制备方法
EP3261582B1 (en) * 2015-02-26 2021-01-06 Remodeless CV Ltd. Methods and compositions relating to leptin antagonists
US10105469B2 (en) * 2015-02-26 2018-10-23 Jacob Schneiderman Composition-of-matter and method for treating cardiovascular disorders
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
JP6918365B2 (ja) 2015-08-19 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 脂質化psa組成物および方法
TWI752920B (zh) * 2015-10-12 2022-01-21 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
CA3030974A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
PT3509624T (pt) * 2016-09-12 2023-08-28 Amryt Pharmaceuticals Inc Métodos de deteção de anticorpos neutralizantes anti-leptina
EP3538554A1 (en) 2016-11-08 2019-09-18 Regeneron Pharmaceuticals, Inc. Antigen-binding proteins that antagonize leptin receptor
AU2018390811A1 (en) 2017-12-18 2020-07-02 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof
EP3773713A1 (en) 2018-04-06 2021-02-17 Regeneron Pharmaceuticals, Inc. A leptin receptor agonist antibody for use in treating a metabolic dysfunction or hypoleptinemia
CN110183530A (zh) * 2019-06-21 2019-08-30 深圳市亚辉龙生物科技股份有限公司 瘦素免疫原、杂交瘤细胞、单克隆抗体、多克隆抗体及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE29522109U1 (de) * 1994-08-17 1999-12-02 The Rockefeller University, New York, N.Y. Modulatoren des Körpergewichts, korrespondierende Nukleinsäuren und Proteine
AU4672199A (en) * 1998-05-20 1999-12-06 Yale University Modulation of angiogenesis and wound healing
CA2376933A1 (en) * 1999-06-11 2000-12-21 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of leptin activity
WO2001096565A2 (en) * 2000-06-16 2001-12-20 Asterion Limited Binding agents: chimeric ligand/receptor proteins

Also Published As

Publication number Publication date
AU2004291323A1 (en) 2005-06-02
WO2005049655A1 (en) 2005-06-02
EP1692181A1 (en) 2006-08-23
DE10353593A1 (de) 2005-06-23
JP2007536212A (ja) 2007-12-13
CN1984930A (zh) 2007-06-20
US20080118503A1 (en) 2008-05-22
US7807154B2 (en) 2010-10-05
EP1692181B1 (en) 2012-01-11
ATE540979T1 (de) 2012-01-15
ES2380341T3 (es) 2012-05-10

Similar Documents

Publication Publication Date Title
DK1692181T3 (da) Leptinantagonist og fremgangsmåde til kvantitativ måling af leptin
NO20072721L (no) Polypeptides that bind BR3 and uses thereof
ATE461449T1 (de) Verfahren zum nachweis von medizinisch relevanten zuständen in gelösten lbc-proben
NO20062886L (no) IL-23 og dens reseptor, beslektede reagenser og fremgangsmater
EA201000245A1 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
BR0315161A (pt) Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição
DK1287130T3 (da) Cytokinreceptorunderenhedproteiner fra pattedyr, tilhörende reagenser og fremgangsmåder
EP1687283A4 (en) PROCESS AND COMPOSITION FOR DETERMINING FK 506
DE60130538D1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
BRPI0509419A (pt) método de ensaio imunossorvente ligado por enzimas, anticorpos, hibridoma e kit de imunoensaio
DE60331677D1 (de) Kit zur untersuchung von menschlichem niedermolekulargewicht cd14 und antikörper
NO960924L (no) Analysesett
EP1433792A8 (en) Human receptor proteins, related reagents and methods
ATE477278T1 (de) Monoklonaler antikörper gegen humanen frizzled-4- rezeptor
ATE418072T1 (de) Verfahren zur diagnose von gebärmutterhalskrebs
EA200600376A1 (ru) Антагонисты nogo-рецептора
DK1987057T3 (da) Peptidaptamer til neutralisering af bindingen af platelet-antigen-specifikke antistoffer og diagnostiske og terapeutiske applikationer indeholdende den.
DE50212790D1 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
ATE383418T1 (de) Verfahren und zusammensetzungen zur bestimmung glycierter proteine
DE60025022D1 (de) Nachweis von hla-g
WO2006004958A3 (en) Detection or measurement of antibodies to antigenic proteins in biological tissues or samples
DE602004001994D1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
ATE484748T1 (de) Testverfahren zur bestimmung von analyten mittels analytanalogen
WO2005065711A3 (en) Mammalian receptor proteins; related reagents and methods
BRPI0520902A2 (pt) Anticorpo monoclonal ou fragmento de ligação a antigeno do mesmo que se liga a proteinas psca para disgnostico de cancer, metodo para produção dos mesmos, hib'ridoma, polinucleotideo, vetor, celula, composição, ensaio para detectar a presença de uma proteina'psca e metodo de detecção de uma proteina psca